Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
September 21 2016 - 7:30AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company
advancing a new class of oral therapeutics for the treatment of
hepatitis B virus (HBV) infection and novel oral biological
therapeutics for disorders associated with the human microbiome,
today reported its participation in recent HBV scientific meetings
in Asia.
Earlier today, Assembly’s Qi Huang, PhD, presented preclinical
data on the company’s Core Protein Allosteric Modifiers (CpAMs) at
the 2016 International HBV Meeting in Seoul, South Korea, in an
oral session co-chaired by Assembly scientific co-founder Dr. Adam
Zlotnick. Assembly’s CpAMs are direct acting oral compounds that
allosterically modulate HBV core protein, an essential viral
protein involved in multiple critical functions throughout the HBV
lifecycle.
Assembly researchers also participated in the 2nd Nanjing
International Symposium on Oncogenic Viruses & Drug Discovery
and Development held in Nanjing, China, September 16-18, 2016. In
addition, Assembly’s Chief Scientific Officer, Richard Colonno,
PhD, gave a presentation on the company’s HBV program at Nanfang
Hospital in Guangzhou, China, Nanfang Hospital is an affiliate of
Southern Medical University, one of the premier academic medical
institutions in China.
About Assembly Biosciences Assembly
Biosciences, Inc. is a public biotechnology company developing
two innovative platform programs: an HBV-cure program advancing a
new class of oral therapeutics for the treatment of hepatitis B
virus (HBV) infection and a microbiome program developing novel
oral biological therapeutics addressing diseases associated with
the human microbiome. Assembly's HBV-cure program aims to increase
the current low cure rates for chronic HBV. The company’s highly
experienced HBV team has collectively brought more than 10
anti-infective products to the market. They are pursuing several
drug candidates that inhibit multiple viral targets throughout the
HBV lifecycle for possible use alone or in combination therapy. The
company’s microbiome program consists of a fully integrated
platform that includes a robust strain identification and selection
process, methods for strain isolation and growth under current Good
Manufacturing Practices and a patent-pending delivery system,
GEMICELTM, which allows for targeted oral delivery of live biologic
and conventional therapies to the lower gastrointestinal tract. The
lead program from this platform, ABI-M101, is in development for
the treatment of C. difficile infections. Assembly is also
developing additional microbiome product candidates. For more
information, visit assemblybio.com.
Contacts
Corporate:
Assembly Biosciences, Inc.
David Barrett
dbarrett@assemblybio.com
Media:
Barbara Lindheim
212 584-2276
barbara@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024